MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-13-2025
DURECT Corporation Revenue 2011-2026 | DRRX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue DURECT Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.55 M | 19.3 M | 14 M | 30.1 M | 29.6 M | 18.6 M | 49.2 M | 14 M | 19.1 M | 19.4 M | 15.3 M | 53.1 M | 33.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 53.1 M | 8.55 M | 24.9 M |
Quarterly Revenue DURECT Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 447 K | 321 K | 1.93 M | 646 K | 496 K | 1.74 M | 2.08 M | 2.05 M | - | 12 M | 2.08 M | 1.92 M | - | 2.16 M | 2.3 M | 2.21 M | - | 1.81 M | 24.5 M | 1.6 M | 10.7 M | 10.8 M | 25 M | 4.13 M | 3.63 M | 8.04 M | 3.41 M | 3.49 M | 19.5 M | 20.7 M | 4.32 M | 4.57 M | 3.52 M | 3.74 M | 3.16 M | 3.61 M | 5.17 M | 4.74 M | 4.44 M | 4.77 M | 4.27 M | 4.26 M | 4.58 M | 6.29 M | 4.29 M | 2.97 M | 3.92 M | 4.15 M | 3.26 M | 3.83 M | 4.8 M | 41.2 M | 8.94 M | 8.12 M | 7.83 M | 8.6 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 41.2 M | 321 K | 6.28 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
651 K | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M | USA |
 |
Canopy Growth Corporation
CGC
|
269 M | $ 1.12 | 5.19 % | $ 120 M |  Canada |
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
5.18 M | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M | USA |
 |
Evolus
EOLS
|
297 M | $ 5.3 | 28.33 % | $ 342 M | USA |
 |
Cronos Group
CRON
|
46.7 M | $ 2.68 | 3.07 % | $ 1.38 B | Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | - | - | $ 2.06 B |  France |
 |
Harrow Health
HROW
|
272 M | $ 40.19 | 4.11 % | $ 1.48 B | USA |
 |
Jupiter Wellness
JUPW
|
702 K | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
4.53 M | $ 0.57 | 4.45 % | $ 9.95 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
10.4 M | $ 4.43 | -3.17 % | $ 62.3 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
874 K | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
25 M | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
175 M | $ 3.7 | 6.18 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Organogenesis Holdings
ORGO
|
482 M | $ 2.99 | 4.01 % | $ 394 M | USA |
 |
Emergent BioSolutions
EBS
|
1.05 B | $ 8.95 | 0.34 % | $ 458 M | USA |
 |
ProPhase Labs
PRPH
|
123 M | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
152 M | $ 12.18 | 2.4 % | $ 865 M | USA |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
83.6 M | $ 0.9 | 0.09 % | $ 21 M | USA |
 |
Bausch Health Companies
BHC
|
8.76 B | $ 5.6 | -2.36 % | $ 2.04 B | Canada |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
Sundial Growers
SNDL
|
920 M | $ 1.55 | 0.98 % | $ 3.37 M | Canada |
 |
OrganiGram Holdings
OGI
|
160 M | $ 1.4 | 2.41 % | $ 402 M | Canada |
 |
Perrigo Company plc
PRGO
|
4.25 B | $ 11.51 | 1.1 % | $ 1.59 B | USA |
 |
TherapeuticsMD
TXMD
|
1.3 M | $ 2.32 | 4.5 % | $ 24.2 M | USA |
 |
Pacira BioSciences
PCRX
|
542 M | $ 22.46 | 1.63 % | $ 1.04 B | USA |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
71 M | - | - | $ 1.08 B | USA |
 |
Veru
VERU
|
16.9 M | $ 2.63 | 4.36 % | $ 355 M | USA |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
15.4 B | $ 14.93 | 0.24 % | $ 17.9 B | USA |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 4.76 | 1.93 % | $ 143 M | USA |
 |
cbdMD
YCBD
|
19.5 M | $ 0.85 | 8.87 % | $ 3.67 M | USA |
 |
SCYNEXIS
SCYX
|
140 M | $ 0.73 | -2.82 % | $ 34.9 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
14.3 M | $ 2.73 | -0.91 % | $ 3.39 M | USA |
 |
Tilray
TLRY
|
627 M | $ 7.56 | 2.65 % | $ 4.67 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
86 K | - | - | $ 55.5 M | USA |